ProCE Banner Activity

CARISEL: Clinical Outcomes by Implementation Strategy of Patients Receiving LA CAB + RPV in European Healthcare Settings

Slideset Download
Conference Coverage

Long-acting cabotegravir plus rilpivirine was effective and well tolerated at 12 months regardless of implementation support in this phase IIIb study.

Released: October 26, 2022


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare